(Q44517812)

English

An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies

scientific article published in July 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

phase II clinical trial

0 references

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jonathan S. Serody

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

Thomas C Shea

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Rebecca Bruner

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Joseph M Wiley

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Scott Sailer

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Don A Gabriel

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Eileen Capel

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Dominic T Moore

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Georgette Dent

9

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Stuart Bentley

10

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Mark E Brecher

11

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 July 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Biology of Blood and Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

443-452

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Is there an association between total-body irradiation and secondary acute myelogenous leukemia/myelodysplastic syndrome in patients with relapsed/refractory Hodgkin's disease treated with autologous stem-cell transplantation?

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: differences between peripheral blood stem cell and bone marrow recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Improve the outcome of autologous hematopoietic cell transplantation!

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900204-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1083-8791(03)00204-0

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44517812&oldid=2026607226"